Breadcrumb
  1. Home
  2. FY 2024 Manufacturer Audit Results

FY 2024 Manufacturer Audit Results

Updated 7/29/2024. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.

Results posted for 5 audits.
Manufacturer Sort descending Labeler Codes Reviewed State OPA Findings Sanction Corrective Action Status
Amryt Pharmaceuticals, Inc. 10122
69880
76431
NC

No adverse findings

None

N/A

Audit closure date: May 14, 2024

Ascend Laboratories, LLC 53097
67877
NJ

No adverse findings

None

N/A

Audit closure date: May 2, 2024

Asegua Therapeutics, LLC 15584
55135
61958
71287
72626
CA

No adverse findings

None

N/A

Audit closure date: May 15, 2024

B. Braun Medical, Inc. 264 PA

B. Braun charged more than the 340B ceiling price.

B. Braun did not determine the difference between new drug price estimates and actual 340B ceiling price and offer a refund.

Repayment to covered entities

Pending

Sun Pharmaceutical Industries, Inc. 47335
10631
41616
49708
51660
51672
53489
57664
62756
63304
67308
70095
NY

Incorrect 340B OPAIS record - Incorrect entry in 340B OPAIS for Authorizing Official and Primary Contact information, manufacturer name, and labeler codes and addresses.

Sun charged more than the 340B ceiling price.

Sun did not determine the difference between new drug price estimates and actual 340B ceiling prices and offer a refund.

Sun failed to refund covered entities for charges that were more than the 340B ceiling price.

Sun did not submit quarterly pricing to 340B OPAIS pricing component.

Repayment to covered entities

Pending

Fecha de la última revisión: